Research Associate in Global Health and Social Medicine; Instructor in Medicine

Phone:

(617) 432-7219

gvelasquez@bwh.harvard.edu

Tabs

Research

Dr. Velásquez's main research interest is to develop safe, tolerable, and effective treatment regimens for drug-susceptible and drug-resistant tuberculosis (TB). He has experience in programmatic evaluations of multidrug-resistant tuberculosis (MDR-TB) screening and drug-resistance testing in Peru; in outcomes research evaluating MDR-TB regimen composition and TB/HIV coinfection management in the Russian Federation and Peru; and in a dose-ranging Phase II clinical trial of rifampin for drug-susceptible tuberculosis.

Dr. Velásquez currently works with Carole Mitnick, ScD and her group as a research associate and co-investigator on two randomized controlled clinical trials: [1] a Phase II trial (HIRIF) examining the potential of high-dose rifampin to shorten standard TB therapy in Peru; and [2] a Phase III trial (endTB) evaluating new shortened oral regimens for the treatment of MDR-TB in Georgia, Kazakhstan, Kyrgyzstan, Lesotho, Peru, and South Africa.

Bio

Gustavo E. Velásquez, MD, MPH, is an associate physician in the Division of Infectious Diseases at Brigham and Women’s Hospital. He is an instructor in the Department of Medicine and a research associate in the Department of Global Health and Social Medicine at Harvard Medical School. Dr. Velásquez received his MD from the Northwestern University Feinberg School of Medicine and his MPH from the Harvard T.H. Chan School of Public Health in 2009. He completed his residency in Global Health Equity and Internal Medicine at Brigham and Women’s Hospital in 2013, and his fellowship in Infectious Diseases at Massachusetts General Hospital and Brigham and Women’s Hospital in 2015.

Publications

Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru.